The Association of Indian Medical Device Industry (AiMeD) welcomes the timely intervention of Mr. Tukaram Mundhe, FDA Maharashtra, in highlighting the alarming markups on essential medical devices such as IV sets, syringes, and cannulas. His survey showing margins as high as 2,841% underscores what AiMeD has consistently cautioned: the current regulatory framework under the Drugs (Prices Control) Order, 2013 is inadequate for medical devices.

Patients, who cannot bargain or choose devices, are left vulnerable to inflated MRPs, while ethical manufacturers and importers are forced to either play within a distorted system or exit the market. This situation penalises both consumers and responsible suppliers, eroding trust and competitiveness.

AiMeD has long advocated for a Fair Pricing Policy tailored to medical devices, with transparent trade‑margin caps based on ex‑factory or landed import prices. Such a system would ensure affordability for patients, encourage ethical competition, and strengthen the “Make in India” vision.

We urge regulators and policymakers to act on Mr. Mundhe’s call by instituting structured price monitoring and margin rationalisation , starting with some pilot studies on AiMeDs proposals as Policy making by evidence.Patients deserve fair prices, not inflated margins, and India deserves a medical device ecosystem that is affordable, ethical, and globally competitive.